The US bank JP Morgan Chase & Co. has confirmed its assessment for the Merck KGaA stock and remains "Overweight". Analyst Richard Vosser continues to see the price target at 155 euros – about 37 percent above the current price of approximately 113 euros.
In his new analysis, Vosser slightly adjusts his forecasts: He is one percent more optimistic than the market consensus on operating profit, but somewhat more cautious about the surplus. For the upcoming quarterly report, the analyst expects stable figures and a confirmation of the annual targets. This would support the current market opinion on the Darmstadt stock.
According to JP Morgan, Merck remains one of the more promising stocks in the European pharmaceutical sector - especially if the results continue at the current level throughout the year.
